Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 7/20 | 0.58 |
| ▸ | NOS2 | P35228 | 7/20 | 0.58 |
| ▸ | NOS1 | P29475 | 6/20 | 0.58 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420102 | 0.77 | GAA (0.42) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL16187962 | 0.74 | S1PR2 (0.38) | NOS3NOS2NOS1KMT2AMEN1 | |
| SCHEMBL29637542 | 0.74 | — | — | |
| SCHEMBL331515 | 0.74 | — | — | |
| SCHEMBL19866691 | 0.72 | CSNK1A1 (0.38) | NOS3NOS2NOS1EGFRKDM4E | |
| SCHEMBL29635160 | 0.72 | CSNK1A1 (0.38) | NOS3NOS2NOS1EGFRKDM4E | |
| Hydrochloric Acid SCHEMBL7051400 | 0.72 | NOS3 (0.95) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL13351204 | 0.72 | — | — | |
| SCHEMBL28056546 | 0.71 | GPBAR1 (0.56) | NOS3NOS2NOS1EGFRPDPK1 | |
| SCHEMBL623346 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20210363130-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584737-B2 | Heterocyclic compound | CDK12, CDK1, CDK15 | NOS3 3886/4885NOS2 2319/4885NOS1 3496/4885 |
| US-20210363130-A1 | HETEROCYCLIC COMPOUND | CDK12, CDK1, CDK15 | NOS3 3886/4885NOS2 2319/4885NOS1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.